Stocks · News reference
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the selling stockholders (the "selling stockholders") identified in this prospectus supplement of up to an
Read original at benzingaWells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.
Read original at benzingaMannKind (NASDAQ:MNKD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $(0.00) by Infinity percent. This is a 120 percent decrease over earnings of $0.05 per share from the
Read original at benzinga